<PAGE>
Securities and Exchange Commission
Washington, D.C. 20549
FORM 8-K/A
AMENDMENT NO. 3 TO
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
July 21, 2000
IMX PHARMACEUTICALS, INC.
-------------------------
(Exact name of Registrant as specified in its charter)
Commission File Number 000-30294
---------
Utah 87-0394290
------------------------------- -------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2295 Corporate Boulevard, Suite 131, Boca Raton, Florida 33431
--------------------------------------------------------------
(Address of Principal Executive Offices)
561.998.5660
------------
(Registrant's Telephone number, including area code)
<PAGE>
IMX PHARMACEUTICALS, INC.
INDEX
Page Number
Item 7
Consolidated Statements of Changes in Stockholders' Equity 1999
(audited) and June 30, 2000 IMX Pharmaceuticals, Inc. (unaudited)
<PAGE>
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934,
the registrant has caused this report to be signed in its behalf by the
undersigned thereunto duly authorized on the 2nd day of October 2000.
IMX PHARMACEUTICALS, INC.
By: /s/ Leonard F. Kaplan
----------------------
Leonard F. Kaplan, Chief Financial Officer
<PAGE>
IMX PHARMACEUTICALS, INC.
AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
CHANGES IN STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
PREFFERED STOCK COMMON STOCK
------------------------- ------------------------- ADDITIONAL
NUMBER NUMBER PAID-IN
OF SHARES AMOUNT OF SHARES AMOUNT CAPITAL (DEFICIT)
----------- ----------- ----------- ----------- ----------- -----------
Balance - December 31, 1998 86,424 $ 86 8,728,108 $ 8,728 $ 7,780,988 $(4,883,487)
Comprehensive Income:
Net income 577,932
Change in other comprehensive income
Total comprehensive income
Preferred stock dividend declared 1,736 2 43,398 (43,400)
Compensation - fair value of common
stock options issued to non-employees 44,483
Conversion of preferred stock to
common stock (88,160) (88) 881,600 882 (794)
Exercise of common stock options 5,000 5 4,995
Transfer of redeemed common stock to
treasury stock 19,999 20 69,980
Conversion of loan receivable to
treasury stock
Purchase of treasury stock
----------- ----------- ----------- ----------- ----------- -----------
Balance - December 31, 1999 0 0 9,634,707 9,635 7,943,050 (4,348,955)
Issuance of common stock for
acquisition of Select Benefits 100,000 100 74,900
Comprehensive Income:
Net income (1,206,347)
Change in other comprehensive income
Total comprehensive income
----------- ----------- ----------- ----------- ----------- -----------
Balance - June 30, 2000 0 $ 0 9,734,707 $ 9,735 $ 8,017,950 $(5,555,302)
=========== =========== =========== =========== =========== ===========
<CAPTION>
TREASURY STOCK
------------------------ OTHER TOTAL
NUMBER COMPREHENSIVE STOCKHOLDERS'
OF SHARES AMOUNT INCOME EQUITY
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Balance - December 31, 1998 3,724,757 $ (357,657) $ 11,000 $ 2,559,658
-----------
Comprehensive Income:
Net income 577,932
Change in other comprehensive income (32,751) (32,751)
-----------
Total comprehensive income 545,181
Preferred stock dividend declared 0
Compensation - fair value of common
stock options issued to non-employees 44,483
Conversion of preferred stock to
common stock 0
Exercise of common stock options 5,000
Transfer of redeemed common stock to
treasury stock 19,999 (70,000) 0
Conversion of loan receivable to
treasury stock 76,000 (125,400) (125,400)
Purchase of treasury stock 11,490 (24,997) (24,997)
----------- ----------- ----------- -----------
Balance - December 31, 1999 3,832,246 (578,054) (21,751) 3,003,925
Issuance of common stock for
acquisition of Select Benefits 75,000
Comprehensive Income:
Net income (1,206,347)
Change in other comprehensive income 8,730 8,730
-----------
Total comprehensive income (1,197,617)
----------- ----------- ----------- -----------
Balance - June 30, 2000 3,832,246 $ (578,054) $ (13,021) $ 1,881,308
=========== =========== =========== ===========
</TABLE>
See accompanying notes to consolidated financial statements.
4
